-
FDA Concerned About Golodirsen as Exon 53 Skipping Duchenne Therapy
The FDA has concerns about the risk of infections upon injection of the therapy golodirsen, and possible toxiciticy to the kidneys. Click here to read more.
Do you agree with the FDA’s concerns?
Sorry, there were no replies found.
Log in to reply.